Status:
COMPLETED
Evaluation of the Drug-drug Interaction Between FosD and Verapamil When Taken Together in Healthy Volunteers
Lead Sponsor:
AstraZeneca
Conditions:
Drug Drug Interactions
Healthy Volunteers
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This Study evaluates the possible drug interaction between FosD and verapamil when taken together.
Detailed Description
An Open-label, Single-Centre Study to Assess the Pharmacokinetics of R406 in Healthy Volunteers when Fostamatinib Disodium 150 mg is Administered Alone and in Combination with Verapamil.
Eligibility Criteria
Inclusion
- Weight of at least 50 kg (110 lbs) and body mass index (BMI) between 18 and 35 kg/m2, inclusive.
- Females must be of non-childbearing potential
Exclusion
- History of clinically significant disease or disorder or presence of GI, hepatic or renal disease
- Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of the drug
- Any clinically significant abnormalities in lab safety tests or vital signs as results as judged by the Investigator
- Use of prescription or over-the-counter drugs within 2 weeks of first administration of investigational product
- Current smokers or use of nicotine products within 1 month prior to enrollment
Key Trial Info
Start Date :
September 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2010
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01197781
Start Date
September 1 2010
End Date
October 1 2010
Last Update
November 23 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Recruiting Site
Overland Park, Kansas, United States